EGFR and non-small cell lung carcinoma: Although the basic correlation between poor prognosis and minor-frequency preT790M in resected EGFR-mutated NSCLC has not yet been elucidated, osimertinib treatment may have had an impact on DFS for the population harboring potential preT790M in the ADAURA trial.